News
Human trials for world’s first AI-designed immuno-oncology drug
Exscientia has announced that the world’s first artificial intelligence (AI)-designed molecule for immuno-oncology has entered human clinical trials.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Exscientia has announced that the world’s first artificial intelligence (AI)-designed molecule for immuno-oncology has entered human clinical trials.